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ABSTRACT
To investigate clinical characteristics of early central nervous system (CNS) complications after reduced-
intensity stem cell transplantation (RIST), we reviewed the medical records of 232 patients who had undergone
RIST for hematologic diseases at our institutions between September 1999 and June 2003. All patients had
received purine analog–based preparative regimens. Stem cell sources comprised granulocyte colony-stimu-
lating factor–mobilized blood from HLA-identical or 1 locus–mismatched related donors (n  151), unrelated
bone marrow (n  44), or unrelated cord blood (n  37). Graft-versus-host disease prophylaxis incorporated
cyclosporine with or without methotrexate. Diagnosis of CNS complications was based on clinical, radiologic,
and microbiological findings. CNS complications occurred in 18 patients (7.8%), with a median onset of 22
days, and were infectious (n  1), metabolic (n  15), or cerebrovascular (n  2). Symptoms included seizures
(n  7), visual disturbance (n  2), headache (n  8), nausea (n  8), vomiting (n  6), impaired consciousness
(n 16), and hemiparesis (n 3). Complications improved promptly in 10 patients, and 8 patients died without
improvement within 30 days. Multivariate analysis with logistic regression identified umbilical cord blood
transplantation as a significant risk factor for early CNS complications (odds ratio, 14.5; 95% confidence
interval, 3.7-56.9; P < .0001). CNS complications are a significant problem after RIST, particularly with
umbilical cord blood. Limbic encephalopathy is an unrecognized subtype of neurotoxicity after umbilical cord
blood transplantation.
© 2004 American Society for Blood and Marrow Transplantation
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HNTRODUCTION
Research in the area of neurologic complications is
imited with regard to allogeneic hematopoietic stem
ell transplantation (allo-HSCT). Most studies have
een either retrospective or reliant on autopsy records
1–6]. Prospective evaluation of this complication hasm.K. and S.M. contributed equally to this article.
B &MTeen rare [7,8]. The incidence of neurologic compli-
ations has varied from 37% to 91%, and such com-
lications have been the cause of death in 6% to 26%
f patients [1,3,8]. These ﬁndings indicate that neu-
ologic complications represent a signiﬁcant problem
n conventional myeloablative allo-HSCT.
Neurologic complications occur at 3 stages of allo-
SCT: (1) after the use of conditioning agents for
arrow ablation, (2) during posttransplantation pan-
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5ytopenia, or (3) after immunosuppressive therapies
nd graft-versus-host disease (GVHD) [1–3,9]. These
omplications are usually categorized into 4 groups:
1) infectious, (2) cerebrovascular, (3) metabolic, or (4)
mmune-mediated disorders. Among these 4 types of
eurotoxicity, cerebrovascular disorders and central
ervous system (CNS) infection before engraftment
ave represented signiﬁcant problems in conventional
llo-HSCT [1,4,8]. Whether GVHD can affect the
NS remains controversial [10], and neurotoxicity has
hus been regarded as an early complication after
llo-HSCT.
A new transplantation strategy using a nonmyelo-
blative preparative regimen—reduced-intensity stem
ell transplantation (RIST)—was developed to de-
rease regimen-related toxicity while preserving ade-
uate antitumor effects [11,12]. Different pioneering
onditioning regimens for RIST have been investi-
ated, such as those including purine analogs [11–13]
nd total body irradiation (TBI) combined with potent
mmunosuppressants [14]. Although early reports on
IST emphasized safety advantages [11,15], recent
tudies have revealed considerable toxicities associated
ith this type of transplantation [16,17]. Little infor-
ation is available on CNS complications after RIST.
e investigated early CNS complications after RIST
ith regard to incidence, characteristics, and risk fac-
ors.
ATIENTS AND METHODS
atients
Medical records of all patients who underwent
IST for treatment of hematologic diseases at the
ational Cancer Center Hospital or Toranomon
ospital between September 1999 and June 2003
ere reviewed. Subjects comprised 232 patients (143
en and 89 women) with a median age of 54 years
range, 15-73 years). Primary diseases consisted of
cute myeloid leukemia (n  63), chronic myeloge-
ous leukemia (n  15), acute lymphoblastic leukemia
n 8), malignant lymphoma (n 67), myelodysplas-
ic syndrome (n  42), adult T-cell leukemia/lym-
homa (n  17), multiple myeloma (n  10), aplastic
nemia (n  8), and others (n  2). Hematologic
alignancies were refractory to cytotoxic chemother-
py in 142 patients and were in remission or sensitive
o treatment in 81 patients. Underlying diseases were
ot malignant in the remaining 9 patients.
ransplantation Procedures
All patients had received purine analog–based pre-
arative regimens comprising ﬂudarabine/cyclophos-
hamide (n 12) [18], ﬂudarabine/busulfan (n 139)
19], ﬂudarabine/melphalan (n  55) [20], cladribine/ t
62usulfan (n  25) [13], and others (n  1). Rabbit
ntithymocyte globulin and TBI (4-8 Gy) were added
o preparative regimens in 50 and 65 patients, respec-
ively.
Stem cell sources were HLA-identical or 1 locus–
ismatched granulocyte colony-stimulating factor–
obilized peripheral blood (n  151), unrelated bone
arrow (n  44), or unrelated umbilical cord blood
n  37). GVHD prophylaxis was cyclosporine alone
3 mg/kg) in RIST from an HLA-identical related
onor and reduced-intensity umbilical cord blood
ransplantation (RI-UCBT). Patients who received
ransplants from a 1 locus–mismatched related donor
r a matched unrelated donor received cyclosporine
nd short-term methotrexate. Grade II to IV acute
VHD was treated with methylprednisolone 2 mg/
g/d in addition to cyclosporine.
iagnostic Criteria for Early CNS Complications
Early CNS complications were deﬁned as CNS
oxicity occurring within 100 days of transplantation.
iagnosis of CNS complications was made by clinical,
adiologic, or microbiological ﬁndings (or a combina-
ion of these). CNS complications were categorized
nto 4 groups: (1) infectious, (2) cerebrovascular, (3)
etabolic, and 4) immune-mediated disorders. CNS
omplications that occurred after relapse or progres-
ion of underlying diseases were excluded from anal-
sis. Diagnosis of cyclosporine encephalopathy was
ased on the typical radiologic ﬁndings, ie, symmet-
ical white matter lesions mainly localized in the oc-
ipital lobe. In the case of limbic encephalopathy, the
iagnosis was based on selective involvement of the
edial temporal lobe on magnetic resonance imaging
MRI). Diagnosis of cerebrovascular diseases was con-
rmed by neuroradiologic or postmortem studies (or
oth). Abnormalities on imaging were deﬁned as areas
f low white-matter attenuation on computed tomo-
raphic (CT) scans and as areas of T1-weighted hy-
ointensity and T2-weighted hyperintensity on MRI.
nd Points and Statistical Analysis
The primary end point of this study was incidence
f early CNS complications after RIST. A secondary
bjective was to investigate characteristics and risk
actors for such complications. The median follow-up
f surviving patients was 17.5 months (range, 8.5-52.7
onths).
Univariate analysis with 2 and Mann-Whitney
ests was performed to identify risk factors for CNS
oxicity. Variables included age, sex, primary disease,
isease status (refractory or sensitive to cytotoxic che-
otherapy), and type of transplantation. We added
ultiple logistic regression analysis to assess the frac-
ionated contribution of the above-mentioned poten-
ially predictive factors. Variables that had a P value of
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CNS Complications after RIST
B.25 on univariate analysis were entered into the
ixed-effects model. Those that contributed 10%
o the overall ability of the model to inﬂuence serum
evels of ﬂuconazole were sequentially eliminated.
he level of signiﬁcance was set at P  .05.
ESULTS
ncidences and Types of CNS Complications after
IST
A total of 18 patients (7.8%) developed early CNS
omplications. Subtypes comprised infectious (inva-
ive aspergillosis; n  1), metabolic (n  15; cyclo-
porine neurotoxicity, n  4; limbic encephalopathy,
 4; hemophagocytic syndrome, n  1; leukoen-
ephalopathy, n  1; idiopathic, n  5), and cerebro-
ascular (subdural hematoma, n  1; subarachnoid
emorrhage, n  1) complications. No patient was
iagnosed with immune-mediated CNS toxicity.
linical and Laboratory Features at Onset of CNS
omplications
Backgrounds of the patients who developed CNS
omplications are shown in Table 1. Except for a
atient with aplastic anemia, the remaining 17 patients
ad refractory hematologic diseases.
Clinical and laboratory ﬁndings at the onset of
NS complications are shown in Table 2. The me-
ian onset was 22 days (range, 1-74 days). Seizures
eveloped in 7 patients (generalized, n  6; focal, n 
). Other symptoms included headache (n  8), nau-
ea (n  8), vomiting (n  6), impaired consciousness
n  16), and hemiparesis (n  3). Two of 11 evalu-
ble patients developed visual disturbance (blurred
ision). Cyclosporine blood levels were higher than
arget levels (250-350 ng/mL) in 4 patients. Nine
atients displayed fever at the onset of CNS compli-
ations, and 2 patients were receiving steroid therapy
or acute GVHD. Concomitant conditions in the 15
atients with metabolic encephalopathy included
ystolic hypertension (170 mm Hg) in 6 patients,
iastolic hypertension (100 mm Hg) in 6, hypo-
atremia in 8, hypomagnesemia in 6, and hypocholes-
erolemia in 4. Cerebrospinal ﬂuid obtained from 5
atients showed normal levels of protein and cell
ounts. No pathogens such as bacteria, fungi, or vi-
uses were cultured from cerebrospinal ﬂuid.
maging Studies
Seventeen patients underwent cranial imaging
tudies: CT only in 6, MRI only in 4, and both CT
nd MRI in 7. Results are shown in Table 2. Of the 14
atients with metabolic encephalopathy who under-
ent imaging studies, 7 displayed some abnormal
ndings. Lesions were located bilaterally in the occip-
tal lobes (n  3), temporal lobes (n  3), or periven- c
B&MTricular white matter (n  1). Three patients who had
eceived UCBTs were diagnosed with limbic enceph-
lopathy on the basis of imaging studies (Figure 1).
reatment and Outcomes
Cyclosporine was continued (n  4) or withheld
n  14) for 1 to 14 days. Two patients received
ntihypertensive agents. Corticosteroids were used in
6 patients. In most patients, subsequent treatment
ith cyclosporine was well tolerated without recur-
ence of neurotoxicity.
Eight patients died within 30 days of developing
NS complications. Causes of death included disease
rogression (n  1), subarachnoid hemorrhage (n 
), GVHD (n  3), and infection (n  3). CNS
omplication was a primary cause of death in 2 cases
invasive aspergillosis, n  1; subarachnoid hemor-
hage, n  1).
isk Factors
In univariate analysis, the development of CNS
omplications was associated with the use of umbilical
ord blood (P  .0001) and the status of underlying
isease (chemorefractory hematologic diseases versus
thers; P  .032). Multivariate analysis showed that
he use of umbilical cord blood was signiﬁcantly cor-
elated with CNS complications after RIST (odds
atio, 14.5; 95% conﬁdence interval, 3.7-56.9; P 
0001).
ISCUSSION
In this study, CNS complications occurred in
.8% of RIST recipients, and mortality with 30 days
f its development reached 44%. These ﬁndings in-
icate that early CNS complications are a common
nd important problem in both RIST and conven-
ional allo-HSCT [1,3,4,8]. However, signiﬁcant dif-
erences existed in clinical characteristics of CNS
omplications between RIST and conventional my-
loablative allo-HSCT.
The incidence of CNS complications was lower in
IST than in conventional allo-HSCT, in which 11%
o 44% of patients develop such complications [2,6,7].
n conventional transplantation, the most common
auses of CNS complications are cerebrovascular dis-
ase and infection after conventional transplantation
1,4,8], and these are mostly attributable to regimen-
elated toxicity [21,22] or profound myelosuppression
efore engraftment [1,3,4]. However, in RIST, regi-
en-related toxicities are minimal, and myelosuppres-
ion is short. Acute GVHD, as the most important
omplication in RIST [16], rarely affects the CNS
23]. RIST has, at the very least, improved the safety
f allo-HSCT by decreasing the incidence of CNS
omplications.
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Table 1. Backgrounds of Patients Who Developed CNS Complications after RIST
Patient
No.
Type of CNS
Complication
Age
(y) Sex Primary Disease
History of
CNS
Involvement
No. of
Chemotherapy
Regimens before
Transplantation Preparative Regimen GVHD Prophylaxis Stem Cell Source
1 Cerebrovascular 57 M ALL Yes 1 Flu/BU/ATG Cyclosporine HLA-identical sibling
2 Cerebrovascular 32 F Malignant lymphoma No 1 Flu/Mel/TBI 4 Gy Cyclosporine Umbilical cord blood
3 Infectious 40 M MDS No 2 Flu/Mel/TBI 4 Gy Cyclosporine Umbilical cord blood
4 Metabolic 21 M Aplastic anemia No 1 Flu/BU/ATG Cyclosporine HLA-identical sibling
5 Metabolic 67 M Malignant lymphoma No 1 Flu/Mel/TBI 4 Gy Cyclosporine Umbilical cord blood
6 Metabolic 67 M MDS No 1 Flu/BU/TBI 4 Gy/ATG Cyclosporine/Methotrexate Matched unrelated donor
7 Metabolic 51 M AML No 2 Flu/BU/TBI 4 Gy Cyclosporine Umbilical cord blood
8 Metabolic 52 M MDS No 2 Flu/ATG Cyclosporine Mismatched related donor
9 Metabolic 49 M ALL No 1 Flu/BU Cyclosporine HLA-identical sibling
10 Metabolic 48 F AML Yes 3 Flu/BU/ATG Cyclosporine/Methotrexate Mismatched related donor
11 Metabolic 57 F AML No 1 Flu/Mel/TBI 4 Gy Cyclosporine Umbilical cord blood
12 Metabolic 66 M Malignant lymphoma No 2 Flu/Mel/TBI 4 Gy Cyclosporine Umbilical cord blood
13 Metabolic 63 M MDS No 1 Flu/Mel/TBI 4 Gy Cyclosporine Umbilical cord blood
14 Metabolic 54 M AML No 1 Flu/Mel/TBI 4 Gy Cyclosporine Umbilical cord blood
15 Metabolic 55 M Malignant lymphoma No 1 Flu/Mel/TBI 4 Gy Cyclosporine Umbilical cord blood
16 Metabolic 62 F ATL No 1 Flu/Mel/TBI 4 Gy Cyclosporine Umbilical cord blood
17 Metabolic 46 M ATL No 1 Flu/Mel/TBI 4 Gy Cyclosporine Umbilical cord blood
18 Metabolic 54 F ATL No 1 Flu/Mel/TBI 4 Gy Cyclosporine Umbilical cord blood
AML indicates acute myeloblastic leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; ATL, adult T-cell leukemia/lymphoma; Flu, ﬂudarabine; BU, busulfan; ATG,
antithymocyte globulin; TBI, total body irradiation; CNS, central nervous system.
Y.K
ishiet
al.
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Table 2. Clinical, Laboratory, and Radiologic Characteristics at the Onset of CNS Complications
Patient
No.
Type of CNS
Complication Cause
Onset
(day)
Clinical Findings
Cyclosporine
(ng/mL)*
Laboratory Findings Radiologic Examination
Electroencephalogram Outcomes
Impaired
Consciousness Seizures
Visual
Disturbance
Fever
(>38.0°C)
Blood
Pressure
(Systolic;
mm Hg)
Blood
Pressure
(Diastolic;
mm Hg)
Creatinine
(mg/dL)
Hemoglobin
(g/dL)
Na
(mEq)
K
(mEq)
Mg
(mEq)
T-Chol
(mg/dL) CT
T2-Weighted
MRI
1 Cerebrovascular 16 No No No No 170 87 386 0.6 9.0 139 4.3 1.5 NA NA Subdural
hematoma
NA Improved
2 Cerebrovascular 40 Yes Yes Yes Yes 152 98 NA 1.6 7 137 3.5 1.3 217 Brain edema,
subarachnoid
hemorrhage
NA NA Dead
3 Infection 68 Yes No No No 108 64 NA 1.2 7.5 136 3.4 0.6 140 Mass in the
parietal lobe
NA NA Dead
4 Metabolic
encephalopathy
Cyclosporine 8 No No No Yes 142 74 316 0.8 6.5 140 4.0 1.5 NA NA Bilateral parietal
and occipital
lobes
NA Improved
5 Metabolic
encephalopathy
Limbic
encephalopathy
22 Yes Yes No No 170 108 219 0.3 8.2 124 3.5 1.2 143 NA Bilateral temporal
lobes
NA Improved
6 Metabolic
encephalopathy
Cyclosporine 22 Yes Yes Not
evaluable
Yes 182 100 266 1.2 7.5 141 2.5 1.8 NA Low-density
area in the
bilateral
occipital
lobes
NA NA Improved
7 Metabolic
encephalopathy
Cyclosporine 22 Yes Yes Not
evaluable
No 120 80 348 1.5 6.5 139 4.8 1.3 107 Normal Bilateral occipital
lobes
NA Improved
8 Metabolic
encephalopathy
Cyclosporine 7 Yes Yes Not
evaluable
Yes 170 78 342 0.8 4.1 138 3.6 1.3 145 Normal NA NA Improved
9 Metabolic
encephalopathy
Hemophagocytic
syndrome
46 Yes No Yes No 130 64 NA 0.7 9.7 139 4.1 NA 110 NA Normal NA Dead
10 Metabolic
encephalopathy
Leukoencephalopathy 12 Yes No No Yes 110 56 NA 1.1 6.5 134 4.0 NA NA Normal Bilateral frontal
and parietal lobes
(periventricular
area)
NA Dead
11 Metabolic
encephalopathy
20 Yes No No No 154 100 584 0.8 8.2 130 2.9 NA 157 Normal NA NA Dead
12 Metabolic
encephalopathy
13 Yes No Not
evaluable
Yes 190 120 511 1.5 8.1 130 4.2 NA 162 Normal Normal Normal Improved
13 Metabolic
encephalopathy
Limbic
encephalopathy
24 Yes No No No 158 85 68 0.8 9.7 131 4.3 NA NA Normal Bilateral temporal
lobes
Diffuse slow waves Improved
14 Metabolic
encephalopathy
22 Yes Yes Not
evaluable
Yes 168 86 416 0.8 7.8 134 3.9 1.3 107 Normal Normal Diffuse slow waves Dead
15 Metabolic
encephalopathy
41 Yes No No Yes 180 120 52 NA NA NA NA NA NA Normal NA Diffuse slow waves Dead
16 Metabolic
encephalopathy
Limbic
encephalopathy
26 Yes Yes Not
evaluable
Yes 174 98 37 2.4 7.4 127 3.4 1.4 130 Normal Bilateral temporal
lobes
Spike wave in frontal
lobes
Dead
17 Metabolic
encephalopathy
18 Yes No Not
evaluable
No 150 100 156 0.4 9.7 113 3.7 NA NA Normal Normal Diffuse slow waves Improved
18 Metabolic
encephalopathy
74 Yes No No No 130 80 NA 2.2 12.1 119 5.4 NA NA NA NA NA Improved
NA indicates not applicable; T-chol, total cholesterol.
*Continuous infusion of cyclosporin was given at target levels of 250-350 ng/mL.
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5In contrast to conventional allo-HSCT, the inci-
ence of metabolic encephalopathy is increased with
IST. In this study, 15 of 18 CNS complications were
etabolic. Of these patients, 4 were diagnosed with
yclosporine encephalopathy on the basis of typical
linical and imaging ﬁndings. The incidence of cyclo-
porine encephalopathy was 1.7% after RIST, which
s comparable to that after conventional allo-HSCT in
oung patients [24]. The median onset was 15 days
range, days 7-22). Three patients displayed seizures
nd altered mental status that improved after discon-
inuation of cyclosporine. Blood levels for cyclospor-
ne were normal in all of the 4 patients. Risk factors
or cyclosporine encephalopathy have been reported
24,25], and hypertension (2/4), hypocholesterolemia
1/2), and hypomagnesemia (3/4) were observed in our
tudy. These ﬁndings are comparable to previous re-
orts on cyclosporine neurotoxicity [24,25]. The
rowing use of RIST has increased the chance of
yclosporine being administered to elderly patients.
ur study does not support the hypothesis that cyclo-
porine neurotoxicity increases in elderly patients, but
urther investigation of the safety issues for cyclospor-
ne is warranted. General management such as blood
ressure control and electrolyte replacement may be
mportant in preventing adverse effects of cyclospor-
ne.
No ﬁndings in the remaining 11 patients with
etabolic encephalopathy suggested cyclosporine en-
igure 1. T2-weighted magnetic resonance image of the brain sh
iagnosed with limbic encephalopathy.ephalopathy. However, it should be noted that all 11 b
66atients received a ﬂudarabine-based preparative reg-
men and that ﬂudarabine has a considerable neuro-
oxicity [26–32]. These ﬁndings suggest that ﬂudara-
ine might have contributed to the development of
NS toxicity in this study. Except for 1 patient with
eukoencephalopathy and hemophagocytic syndrome–
elated CNS complications, the other 10 patients had
ndergone UCBT. The incidence of CNS complica-
ions after RI-UCBT was 24%. Cord blood as a stem
ell source was an independent risk factor in multivar-
ate analysis (odds ratio, 14.5; 95% conﬁdence inter-
al, 3.7-56.9; P  .0001). Few studies on CNS com-
lications after myeloablative UCBT have been
eported. This complication is possibly characteristic
f RI-UCBT. All 10 patients developed altered mental
tatus, including 3 with generalized seizures. Brain
maging in 3 patients showed abnormal signals around
he hippocampus, whereas images were normal in the
ther 6 patients. Hippocampal encephalopathy in the
patients involved both white and gray matter and
as thus distinct from leukoencephalopathy. Similar
ndings after RI-UCBT have recently been reported
33]. Although an association with tacrolimus admin-
stration has been suggested, none of our patients
eceived tacrolimus, thus indicating other causes. Pos-
ibilities include infection, regimen-related toxicity,
nd immune reaction associated with the use of cord
lood. Eight patients who developed metabolic en-
ephalopathy after RI-UCBT had received ﬂudara-
high-intensity signals in bilateral temporal lobes. The patient wasowingine, melphalan, and TBI as a preparative regimen.
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CNS Complications after RIST
Bhis has a higher intensity than most reduced-inten-
ity regimens and might have caused CNS toxicities.
Conversely, CNS complications do not represent
signiﬁcant concern in bone marrow or peripheral
lood transplantation with similar reduced-intensity
egimens. Because adult RI-UCBT recipients receive
relatively low dose of CD34 cells, it would raise the
oncern that there might have been delayed engraft-
ent, leading to an increase in subclinical or undetec-
ed CNS viral infections. However, this possibility
eemed unlikely. In RI-UCBT with ﬂudarabine, mel-
halan, and intermediate-dose TBI as a preparative
egimen and cyclosporine as GVHD prophylaxis [34],
he median day of neutrophil engraftment was 17.5
ays. This is comparable to RIST with granulocyte
olony-stimulating factor–mobilized blood [11,13].
urthermore, neither cerebrospinal ﬁndings nor
lood cultures identiﬁed CNS infection in our study,
nd no patient had GVHD at the onset of CNS
omplications. Because 4 of the 10 patients who un-
erwent RI-UCBT died soon after the development
f CNS complications, symptoms might represent an
arly manifestation of a systemic disorder predispos-
ng for multiple organ dysfunction syndrome, increas-
ng the risk of transplant-related mortality [35]. How-
ver, the association of CNS complications with
ngraftment is noteworthy in RI-UCBT. We did not
se antithymocyte globulin or corticosteroids for pre-
arative regimens or GVHD prophylaxis, respec-
ively, although these practices have been commonly
sed in previous studies on UCBT [36]. Both agents
isplay strong immunosuppressive properties. The
uid accumulation often observed during this period
ay have accentuated the tendency for brain edema to
evelop, as seen in patients with renal decompensa-
ion. In RI-UCBT with our regimens [34], the cumu-
ative incidence of complete donor chimerism at day
0 was 93%, and the median time to complete donor
himerism was 22 days. Grade II to IV acute GVHD
ccurred in 27% of patients. Approximately 60% of
I-UCBT recipients had a noninfectious fever before
ngraftment (median onset, day 9). Manifestations in-
luded a high-grade fever, eruption, and diarrhea, and
orticosteroids were effective for ameliorating these
eactions. These ﬁndings suggest that they might be
ssociated with a cytokine storm induced by massive
roliferation of cells with a unique cytokine proﬁle
nd that the CNS toxicity was attributable to these
mmune responses. We therefore treated the CNS
oxicity with corticosteroids. Because CNS toxicity is
ssociated with considerable morbidity and mortality,
ptimal preventive measures for CNS complications
fter RI-UCBT should be established. Intensiﬁcation
f GVHD prophylaxis, such as with methotrexate,
ight prove beneﬁcial for this purpose.
This investigation was a retrospective study basedn medical records. Pathologic examinations were not
B&MTsed in most patients, and diagnosis of CNS compli-
ations was established on the basis of clinical and
adiologic ﬁndings. Mild neurotoxicity associated with
llo-HSCT was likely neglected, and incidences might
ave been underestimated in this study. Compared
ith autopsy studies, approximately half of the pa-
ients with neurologic complications had been diag-
osed during life [4]. Further prospective evaluation is
arranted to clarify incidences and clinical character-
stics for CNS complications after RIST and to estab-
ish optimal preventive and therapeutic measures.
In conclusion, we have demonstrated that CNS
omplications are a common and frequently fatal com-
lication after RIST, particularly after the use of um-
ilical cord blood. Metabolic encephalopathy is the
ost common subtype of CNS complication after
IST, and it frequently manifests as limbic encepha-
opathy in RIST with umbilical cord blood.
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